New Aging Clocks Reveal How Drugs Act Differently Across 49 Human Tissues

Aging has long been treated, in the laboratory at least, as a single unified process. The most influential biological age predictors, from the original DNA methylation clocks to their more recent lifespan-oriented successors, were trained on data pooled across many tissues, implicitly assuming that the molecular signature of aging in the brain resembles that in the liver, the heart, or the arteries. A new study published in the journal Biogerontology challenges that assumption at scale, and in doing so opens an unusually candid window into both the promise and the pitfalls of computational drug repurposing for aging research.

The study, conducted by Dongdong Zhang of the Wuwei Center for Disease Control and Prevention in China, constructed not one aging clock but 49 of them: 47 transcriptomic clocks trained on individual human tissue types and two trained on cell-line categories. The underlying data came from the Genotype-Tissue Expression project, known as GTEx version 8, which catalogs gene expression across the human body and contributed samples from 948 unique donors to the retained clock categories. Rather than blending these tissues into a single model, Zhang trained a separate elastic-net regression for each category, predicting chronological age from gene expression, and evaluated every clock using donor-grouped cross-validation, a design that prevents the same individual’s samples from leaking between training and test sets.

The performance of these clocks varied considerably, and that variation is itself informative. The median Pearson correlation between predicted and chronological age across all 49 clocks was 0.543, a respectable but far from perfect figure that reflects the noisy relationship between transcript levels and elapsed time. At the top end, the clock trained on the aorta achieved a correlation of 0.855, making the body’s largest artery the most transcriptionally age-accurate tissue in the dataset. This spread suggests that some tissues carry far stronger and more consistent age-related transcriptional signals than others, a finding consistent with growing evidence from plasma proteome studies that organs age at measurably different rates and that organ-specific aging signatures track health and disease.

Across all clocks, the analysis identified 10,253 unique genes that the elastic-net procedure had selected as age predictors. Strikingly, 69.2 percent of these clock genes appeared in only one tissue, a degree of overlap so low that it might seem to prove that each organ ages through its own dedicated molecular program. But the study did something that many clock papers skip: it ran a null simulation. When the same elastic-net selection procedure was applied to shuffled data, it produced similarly sparse, minimally overlapping gene sets. In other words, the apparent tissue-specificity of clock genes is largely the expected statistical consequence of applying a sparse regularization method to high-dimensional data, not necessarily evidence of profound biological divergence between tissues. It is a methodological caution that ripples well beyond this study, touching any field that interprets which features a machine-learning model selects rather than how well it predicts.

The second half of the study is where the work becomes genuinely provocative for the drug discovery community. Zhang projected 3,926 compound-name entries from the Library of Integrated Network-Based Cellular Signatures, or LINCS L1000, onto each of the 49 tissue clocks. The logic is a familiar one in connectivity-map style analyses: if a drug’s known gene-expression signature pushes a tissue’s aging clock backward, that drug might be a candidate anti-aging compound for that tissue; if it pushes the clock forward, the drug might be accelerating that tissue’s transcriptional aging. The result is a vast drug-by-category matrix of age-reversal scores covering 192,374 drug-tissue pairs, a resource the author describes as tissue-aware and hypothesis-generating.

What emerged from that matrix is a picture of profound drug heterogeneity. At a permissive threshold, with absolute scores above 1.0, 94.2 percent of drugs showed mixed score directions, meaning they appeared to reverse transcriptional aging in some tissue categories while appearing to accelerate it in others. This near-universal mixed behavior, however, was descriptive and did not itself exceed what shuffled data produced, so the study is careful not to claim it as a biological discovery. Under a far more stringent exploratory criterion, requiring absolute scores above 2.0 in at least three categories in each direction, 2.8 percent of compound entries showed pronounced bidirectional divergence, compared with roughly 0.1 percent under the shuffled null. That roughly thirtyfold enrichment over chance suggests that a small subset of compounds genuinely produces structured, tissue-dependent transcriptional signals that cannot be explained by noise alone.

Robustness checks form the backbone of the paper’s credibility. When the compound rankings were recomputed using only the 34 clocks whose correlations reached at least 0.5, the rankings remained highly stable, with a Spearman correlation of 0.897 against the full analysis. A completely independent enrichment method based on Jaccard overlap produced nearly identical compound orderings, with a median per-category Spearman correlation of 0.961, demonstrating that the findings were not artifacts of one particular scoring approach. Four additional statistical robustness tests confirmed model stability. Yet the study is equally forthright about the limits of its own conclusions: after Benjamini-Hochberg false discovery rate correction across all 192,374 drug-category pairs, only 0.79 percent of pairs reached significance at FDR below 0.05. Individual drug-tissue calls, the paper emphasizes, demand caution and experimental validation before anyone treats them as actionable.

One result will raise eyebrows among longevity enthusiasts. Rapamycin, the mTOR inhibitor that robustly extends lifespan in mice and anchors much of the geroscience agenda, showed net pro-aging transcriptional signatures in this system. The author explicitly and repeatedly stresses that transcriptome-based scores and organismal lifespan are distinct endpoints. A drug can shift the expression levels of age-associated genes in adult human tissue samples without shortening or lengthening life, and rapamycin’s well-documented lifespan effects in animal models involve mechanisms, including immune modulation and long-term metabolic reprogramming, that a static transcriptional score cannot capture. The finding is best read as a demonstration of the method’s limits and a warning against equating clock reversal with rejuvenation, rather than as evidence against rapamycin itself.

The study also ventured into causal territory using the Cancer Dependency Map, or DepMap, repeating CRISPR-based gene dependency analyses after standardizing on GTEx-derived data across 13 matched tissue categories. The author acknowledges that individual gene-level results from this component were limited, positioning it as a secondary exploration rather than a headline finding. All datasets used in the study, including GTEx v8, LINCS L1000, and DepMap, are publicly available without application, and the complete analysis code has been released on GitHub, making the entire pipeline reproducible and extensible by other groups.

The broader significance of this work lies less in any single drug-tissue prediction than in the framework it establishes. It shows that tissue-resolved aging clocks are feasible at scale, that their gene selections must be interpreted through the lens of statistical regularization rather than taken as direct biology, and that drug effects on aging signatures are structured but overwhelmingly tissue-dependent. For a field increasingly animated by the prospect of repurposing existing drugs against aging, the message is double-edged: computational screens can generate rich, testable hypotheses about which compounds might help which organs, but the same screen that flags a candidate in one tissue may flag the same compound as harmful in another. Bridging that gap between transcriptional pattern and therapeutic reality will require exactly what this study cannot provide: controlled experiments in living systems, tissue by tissue, drug by drug.

Subject of Research: Tissue-specific transcriptomic aging clocks and their use to profile tissue-dependent drug effects on aging across 49 human tissue and cell-line categories

Article Title: Tissue-specific aging clocks map structured aging-modulatory drug-score patterns across 49 human tissue and cell-line categories

Article References: Zhang, D. (2026). Tissue-specific aging clocks map structured aging-modulatory drug-score patterns across 49 human tissue and cell-line categories. Biogerontology, 27(5), Article 163. https://doi.org/10.1007/s10522-026-10512-2

Image Credits: AI Generated

DOI: 10.1007/s10522-026-10512-2

Keywords: aging clock, tissue-specific aging, GTEx, LINCS L1000, drug repurposing, transcriptomics, elastic net, biological age prediction, rapamycin, DepMap, Biogerontology, drug heterogeneity